A limited number of transnational, ambitious, innovative, and high-quality studies on the natural course of rare diseases will be funded, which should enable a better understanding of the course of the disease over the entire life span of a patient.

This may include the use of relevant cell models to validate novel endpoints and biomarkers from disease progression studies.

In the first stage of the procedure, project outlines must initially be submitted in an electronic form to the EJPRD Secretariat, located at the French National Research Agency (ANR), no later than February 15, 2023, 14:00 CET.

Further information:
https://www.bmbf.de/bmbf/shareddocs/bekanntmachungen/de/2023/02/2023-02-03-Bekanntmachung-seltene-Erkrankungen.html